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Over the past few years, de novo lipogenesis has taken 
central stage in the field of cancer metabolism (1). Large 
amount of lipids is needed for synthesis of membranes, 
signaling molecules, lipoproteins, etc. to support rapidly 
growing tumor cells (2-4). Reports have shown that 
neoplastic tissues show aberrant activation of de novo 
lipogenesis and that inhibition of different enzymes 
within the fatty acid biosynthesis pathway can block 
cancer cell growth (2,5-9). Meanwhile, the importance of 
fatty acid oxidation (FAO) in cancer metabolism is being 
increasingly recognized. FAO is the catabolic process by 
which lipids are utilized to produce energy. Recent studies 
implicated that the key regulatory enzymes in FAO such as 
carnitine palmitoyltransferase 1 (CPT1) and peroxisomal 
acyl-coenzyme A oxidase 1 (ACOX1) regulate cancer 
development (10,11). The underlying mechanisms for the 
regulation of de novo lipogenesis and FAO in cancers are, 
however, still incompletely understood. Thus, it would be 
of a high scientiﬁ c and clinical interest to elucidate the lipid 
metabolism in cancer.
Multiple independent laboratories discovered that 
CD147, a transmembrane glycoprotein, is highly expressed 
in hepatocellular carcinoma (HCC) cells and is strongly 
associated with tumor progression (12,13). Licartin, an 
131Iodin-labeled antibody fragment targeting the HCC-
associated antigen HAb18G/CD147, has been approved 
by the Chinese Food and Drug Administration (FDA) and 
enters into clinical use for HCC treatment (14-16). To 
date, studies have shown that CD147 contributes to the 
metabolism of cancer cells via glycolysis (17-19). However, 
a paper recently published in the Journal of Hepatology by Li 
et al. reports that CD147 regulates the lipid metabolism in 
cancer cells (20). 
By analyzing four public datasets of mRNA expression 
in HCC tissues and performing experiments using two 
different HCC cell lines, Li et al. demonstrated that 
CD147 significantly contributed to the reprogramming 
of fatty acid metabolism in HCC cells. They investigated 
the levels of expression of lipogenic enzymes and sterol 
regulatory element binding proteins (SREBPs), and 
activation of Akt/mTOR signaling pathways in tumor cells 
with different CD147 expression levels. Their data showed 
that CD147 activated the Akt/mTOR signaling pathway 
and subsequently up-regulated SREBP1c, leading to the 
increase in transcription of major lipogenic genes, FASN 
and ACC1 to promote de novo lipogenesis.
Next, they analyzed the signaling pathway involved in 
CD147-induced peroxisome proliferator-activated receptor 
alpha (PPARα) regulation. To test whether CD147 inhibits 
the expression of PPARα via activation of P38 MAPK 
signaling pathway, they treated P38 inhibitor SB203580 
to CD147-wild type, CD147-knockout and CD147-
overexpression HCC cells. They found that the inhibition 
of P38 MAPK activity up-regulated PPARα in CD147-wild 
type and CD147-overexpression cells. As well, the treatment 
with SB203580 led to the activation of FAO and decreases 
in the contents of triglyceride, phospholipids and neutral 
lipids. The results suggest that the inhibition of P38 MAPK 
reversed the down-regulation of FAO by CD147 through 
the up-regulation of PPARα in HCC cells. Lastly, they 
found that CD147 knockout or knockdown significantly 
inhibited the proliferation, migration and invasion of 
HCC cells, determined via the MTT assay, wound-healing 
migration assay, trans-well invasion assay, and orthotopic 
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Figure 1 Regulation of fatty acid metabolism by CD147 in HCC cells. Modiﬁ ed from reference (20). 
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xenograft models. Li et al. verified that CD147 increased 
the aggressiveness of HCC cells through the Akt/mTOR/
SREBP1c and P38/PPARα pathways, leading to the up-
regulation of fatty acid synthesis and down-regulation of 
fatty acid oxidation (Figure 1). 
Tumors expressing high levels of CD147 include 
carcinomas of the urinary bladder, breast, lung, oral 
cavity, esophagus, skin, and etc. (21-29). It would be 
interesting to see if CD147 functions likewise as a critical 
regulator of fatty acid metabolism in other types of 
cancer. The study by Li et al. is expected to provide new 
insights into understanding the mechanisms underlying 
the reprogramming of lipid metabolism in HCC and its 
association with HCC proliferation and progression, as 
wells as new strategies for future drug development for 
HCC treatment. 
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